2023 was a troublesome 12 months for the biopharma field, with many companies downsizing and restructuring their workforces to remain afloat. You can find signs of Restoration, as mergers and acquisitions picked up through the pharmaceutical and life sciences business within the latter Portion of 2023 and have ongoing their https://sites.google.com/view/bio-sites/blog